182 related articles for article (PubMed ID: 18608912)
21. Cryptococcus neoformans antibody levels in patients with AIDS.
Dromer F; Aucouturier P; Clauvel JP; Saimot G; Yeni P
Scand J Infect Dis; 1988; 20(3):283-5. PubMed ID: 3043650
[TBL] [Abstract][Full Text] [Related]
22. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival.
Blackstock R; Casadevall A
Immunology; 1997 Nov; 92(3):334-9. PubMed ID: 9486105
[TBL] [Abstract][Full Text] [Related]
23.
Colombo AC; Rella A; Normile T; Joffe LS; Tavares PM; de S Araújo GR; Frases S; Orner EP; Farnoud AM; Fries BC; Sheridan B; Nimrichter L; Rodrigues ML; Del Poeta M
mBio; 2019 Apr; 10(2):. PubMed ID: 30940711
[No Abstract] [Full Text] [Related]
24. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
Maitta RW; Datta K; Pirofski LA
Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
[TBL] [Abstract][Full Text] [Related]
25. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis.
Fleuridor R; Lyles RH; Pirofski L
J Infect Dis; 1999 Nov; 180(5):1526-35. PubMed ID: 10515812
[TBL] [Abstract][Full Text] [Related]
26. Detection of antibodies to phospholipase B in patients infected with Cryptococcus neoformans by enzyme-linked immunosorbent assay (ELISA).
Santangelo RT; Chen SC; Sorrell TC; Wright LC
Med Mycol; 2005 Jun; 43(4):335-41. PubMed ID: 16110779
[TBL] [Abstract][Full Text] [Related]
27. Enzyme-linked immunosorbent assays in murine cryptococcosis.
Scott EN; Muchmore HG; Felton FG
Sabouraudia; 1981 Dec; 19(4):257-65. PubMed ID: 7034237
[TBL] [Abstract][Full Text] [Related]
28. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
Pirofski LA; Casadevall A
Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968
[TBL] [Abstract][Full Text] [Related]
29. [Monoclonal antibodies recognizing the capsular polysaccharide of Cryptococcus neoformans].
Rodríguez Sánchez H; Pupo Antúnez M; Ilnait MT; Otero A; Martínez Machín G
Rev Cubana Med Trop; 2005; 57(2):162-4. PubMed ID: 17966590
[TBL] [Abstract][Full Text] [Related]
30. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
[TBL] [Abstract][Full Text] [Related]
31. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
Mukherjee J; Kozel TR; Casadevall A
J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
[TBL] [Abstract][Full Text] [Related]
33. Variability in innate host immune responses to cryptococcosis.
Garelnabi M; May RC
Mem Inst Oswaldo Cruz; 2018; 113(7):e180060. PubMed ID: 29668826
[TBL] [Abstract][Full Text] [Related]
34. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
35. Semisynthetic Glycoconjugate Vaccine Candidates against
Crawford CJ; Liporagi-Lopes L; Coelho C; Santos Junior SR; Moraes Nicola A; Wear MP; Vij R; Oscarson S; Casadevall A
ACS Infect Dis; 2024 Jun; 10(6):2089-2100. PubMed ID: 38819951
[No Abstract] [Full Text] [Related]
36. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, reduce serotype bias in an immunoassay for cryptococcal antigen.
Percival A; Thorkildson P; Kozel TR
Clin Vaccine Immunol; 2011 Aug; 18(8):1292-6. PubMed ID: 21697342
[TBL] [Abstract][Full Text] [Related]
37. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide.
Lendvai N; Casadevall A; Liang Z; Goldman DL; Mukherjee J; Zuckier L
J Infect Dis; 1998 Jun; 177(6):1647-59. PubMed ID: 9607845
[TBL] [Abstract][Full Text] [Related]
38. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
39. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide.
Goldman DL; Lee SC; Mednick AJ; Montella L; Casadevall A
Infect Immun; 2000 Feb; 68(2):832-8. PubMed ID: 10639453
[TBL] [Abstract][Full Text] [Related]
40. Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies.
Zhong Z; Pirofski LA
Infect Immun; 1996 Sep; 64(9):3446-50. PubMed ID: 8751883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
